EMA is moving forward with Nitrosamines. After a risk assessment phase, the marketing authorisation holders need to test metformin drugs to assess the presence of nitrosamines in their product, after detection of NMDA (N-nitrosodimethylamine ) in some EU batches, see EMA website.
